Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
RNCartesian Therapeutics, Inc. logo

Cartesian Therapeutics, Inc. (RNAC)

NASDAQ · Currency in USD
$6.18 ▼ -0.23 (-3.59%)
At close: Oct 23, 4:00 PM ET. Market closed.
$6.18 ▲ +0.00 (+0.00%)
After hours: Oct 23, 6:44 PM ET

Summary

Previous Close
$6.41
Open
$6.38
Day's Range
$6.11 – $6.38
52 Week Range
$5.60 – $11.00
Volume
85,807
Avg. Volume
160,447
Market Cap
$186.98M
Beta (5Y Monthly)
0.65
PE Ratio (TTM)
--
EPS (TTM)
-$5.22
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$25.00

Profile: Cartesian Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
75
CEO
Carsten Brunn

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$1.02 · Revenue est. $160.00K
DateEst.Actual
Aug 6, 2026-$0.88$0.46Beat
Apr 30, 2026-$0.84-$1.46Miss
Mar 9, 2026-$0.82-$1.38Miss
Nov 6, 2025-$0.81-$1.38Miss
Aug 7, 2025-$0.76$0.50Beat
May 8, 2025-$0.61-$0.68Miss

Analyst view

Consensus price target
$25.00 ▲ +304.5%
Range $25.00 – $25.00
Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Get free alerts on RNAC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.